Globeflex Capital L P Incyte Corp Transaction History

Globeflex Capital L P

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$57.77 - $65.93 $18,948 - $21,625	328 Added 27.99%	1,500 $86,000
Q2 2023 Aug 14, 2023	SELL	$60.95 - $75.51 $16,944 - $20,991	-278 Reduced 19.17%	1,172 $72,000
Q1 2023 May 12, 2023	BUY	$70.23 - $86.01 $101,833 - $124,714	1,450 New	1,450 $104,000
Q2 2022 Aug 15, 2022	SELL	$66.18 - $83.18 $404,425 - $508,312	-6,111 Reduced 22.61%	20,918 $1.59 Million
Q3 2021 Nov 12, 2021	BUY	$68.67 - $84.02 $1.86 Million - $2.27 Million	27,029 New	27,029 $1.86 Million
Q2 2020 Aug 12, 2020	SELL	$74.18 - $108.93 $212,748 - $312,411	-2,868 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$63.18 - $85.97 $181,200 - $246,561	2,868 New	2,868 $210,000

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Globeflex Capital L P, based on Form 13F filings with the SEC.

Stay updated on Globeflex Capital L P with notifications on news.